Ilika plc
("Ilika")
Discontinuing of wound care products and services
Ilika (AIM: IKA), the advanced cleantech materials discovery company, announces that the Company has taken the decision to implement a rationalisation of its biomedical division.
The biomedical division currently operates a high throughput platform for the discovery of novel, biologically active materials as well as the provision of wound care products and services. The rationalisation will involve discontinuing the provision of its wound care products and services with effect from the end of the calendar year. The biomedical division will continue to focus on its core competencies associated with its high throughput operations.
Turnover generated by the wound care business in the financial statements covering the year to 30 April 2012 was £160,072 (total group turnover £2,011,244), with £188,611 generated from its biomedical high throughput activities.
| Ilika plc | www.ilika.com |
| Graeme Purdy, Chief Executive | Tel: 023 8011 1400 |
| Steve Boydell, Finance Director | |
| Numis Securities Limited | Tel: 020 7260 1000 |
| Oliver Cardigan, Nominated Adviser | |
| James Black, Corporate Broking | |
| Walbrook PR Ltd | Tel: 020 7933 8780 |
| Paul McManus | Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
| Paul Cornelius | Mob: 07827 879 460 or paul.cornelius@walbrookir.com |
This information is provided by RNS